Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $474000.0.

  • Avalo Therapeutics' Accounts Payables fell 7382.66% to $474000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $474000.0, marking a year-over-year decrease of 7382.66%. This contributed to the annual value of $283000.0 for FY2024, which is 3654.71% down from last year.
  • Per Avalo Therapeutics' latest filing, its Accounts Payables stood at $474000.0 for Q3 2025, which was down 7382.66% from $2.4 million recorded in Q2 2025.
  • Avalo Therapeutics' Accounts Payables' 5-year high stood at $11.9 million during Q1 2021, with a 5-year trough of $283000.0 in Q4 2024.
  • Moreover, its 5-year median value for Accounts Payables was $1.8 million (2024), whereas its average is $2.5 million.
  • Per our database at Business Quant, Avalo Therapeutics' Accounts Payables soared by 33701.43% in 2021 and then tumbled by 8452.46% in 2023.
  • Avalo Therapeutics' Accounts Payables (Quarter) stood at $3.4 million in 2021, then dropped by 14.46% to $2.9 million in 2022, then plummeted by 84.52% to $446000.0 in 2023, then plummeted by 36.55% to $283000.0 in 2024, then soared by 67.49% to $474000.0 in 2025.
  • Its last three reported values are $474000.0 in Q3 2025, $2.4 million for Q2 2025, and $681000.0 during Q1 2025.